ONCAlert | Upfront Therapy for mRCC

Lung Cancer VIEW MORE >>

For patients with non–small cell lung cancer, having a body mass index ≥30 at baseline could be independently associated with an improvement in overall survival with atezolizumab and could be considered a stratification factor in immune checkpoint inhibitor trials, according to a study published in JAMA Oncology.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.